PMID- 34269290
OWN - NLM
STAT- MEDLINE
DCOM- 20211209
LR  - 20220424
IS  - 1998-4138 (Electronic)
IS  - 1998-4138 (Linking)
VI  - 17
IP  - 3
DP  - 2021 Jul
TI  - Anlotinib followed by transarterial chemoembolization and radiofrequency ablation 
      is a safe and effective initial treatment for hepatocellular carcinoma patients 
      with portal vein tumor thrombus: A retrospective case series study.
PG  - 619-624
LID - 10.4103/jcrt.JCRT_1253_20 [doi]
AB  - BACKGROUND: Portal vein tumor thrombus (PVTT) remains a poor prognostic factor 
      occurring in about 10%-40% of patients with hepatocellular carcinoma (HCC) for 
      the optimal treatment is controversial. Anlotinib is an novel small molecule 
      inhibitor that has a broad spectrum of inhibitory activities on tumor 
      angiogenesis and growth. However, so far, no studies have reported the use of 
      anlotinib in the treatment of HCC patients with PVTT. Here, we evaluated the 
      safety and efficacy of anlotinib, followed by transarterial chemoembolization 
      (TACE) and radiofrequency ablation (RFA) for the treatment of patients with HCC 
      and PVTT. MATERIALS AND METHODS: A total of 145 consecutive HCC patients who 
      underwent TACE in combination with RFA were enrolled in the retrospective study. 
      Twenty-eight patients were diagnosed with PVTT and received anlotinib as basic 
      treatment. The adverse events (AEs) were graded according to the National Cancer 
      Institute Common Terminology Criteria for AEs Version 4.0. Time to tumor 
      progression (TTP) and overall survival (OS) were calculated using the 
      Kaplan-Meier method. RESULTS: The most common toxicities related to anlotinib 
      were pharyngalgia (53.6%), fatigue (42.9%), and hand-foot skin reaction (39.3%). 
      The median OS was 13 months (range: 3-18 months) with 1-year OS rate of 64.3%. 
      The median TTP was 7 months (range: 1-12 months) with 6-month rate of 46.4%. 
      CONCLUSION: Anlotinib followed by TACE and RFA is a safe and effective initial 
      treatment modality for HCC patients with PVTT. Anlotinib may be a promising 
      therapeutic option for relieving and/or stabilizing HCC with PVTT.
FAU - Wang, Jianpeng
AU  - Wang J
AD  - Department of Oncology, First People's Hospital of Foshan, Foshan Hospital of Sun 
      Yat-Sen University, Foshan, China.
FAU - Li, Xishan
AU  - Li X
AD  - Department of Interventional Radiology, Guangzhou First People's Hospital, The 
      Second Affiliated Hospital of South China University of Technology, Guangzhou, 
      China.
FAU - Wang, Fengjie
AU  - Wang F
AD  - Department of Oncology, First People's Hospital of Foshan, Foshan Hospital of Sun 
      Yat-Sen University, Foshan, China.
FAU - Shi, Degang
AU  - Shi D
AD  - Department of Oncology, First People's Hospital of Foshan, Foshan Hospital of Sun 
      Yat-Sen University, Foshan, China.
FAU - Zhang, Jiren
AU  - Zhang J
AD  - Department of Oncology, Zhujiang Hospital, Southern Medical University, 
      Guangzhou, China.
LA  - eng
PT  - Journal Article
PL  - India
TA  - J Cancer Res Ther
JT  - Journal of cancer research and therapeutics
JID - 101249598
RN  - 0 (Indoles)
RN  - 0 (Quinolines)
RN  - 0 (anlotinib)
RN  - 9ZOQ3TZI87 (Sorafenib)
SB  - IM
MH  - Carcinoma, Hepatocellular/complications/mortality/pathology/*therapy
MH  - Catheter Ablation/adverse effects/*methods
MH  - Chemoembolization, Therapeutic/adverse effects/*methods
MH  - Combined Modality Therapy/adverse effects/methods
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Indoles/*administration & dosage/adverse effects
MH  - Kaplan-Meier Estimate
MH  - Liver Neoplasms/complications/mortality/pathology/*therapy
MH  - Male
MH  - Neoplasm Invasiveness/pathology
MH  - Portal Vein/pathology/surgery
MH  - Postoperative Complications/epidemiology/etiology
MH  - Quinolines/*administration & dosage/adverse effects
MH  - Retrospective Studies
MH  - Sorafenib/administration & dosage/adverse effects
MH  - Survival Rate
MH  - Venous Thrombosis/etiology/mortality/*therapy
OTO - NOTNLM
OT  - Anlotinib
OT  - hepatocellular carcinoma
OT  - portal vein tumor thrombus
OT  - radiofrequency ablation
OT  - transarterial chemoembolizationa
COIS- None
EDAT- 2021/07/17 06:00
MHDA- 2021/12/15 06:00
CRDT- 2021/07/16 08:48
PHST- 2021/07/16 08:48 [entrez]
PHST- 2021/07/17 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
AID - JCanResTher_2021_17_3_619_321007 [pii]
AID - 10.4103/jcrt.JCRT_1253_20 [doi]
PST - ppublish
SO  - J Cancer Res Ther. 2021 Jul;17(3):619-624. doi: 10.4103/jcrt.JCRT_1253_20.